ClinicalTrials.gg
Not yet recruitingNCT07060196ADLs AMDUpdated Jul 11, 2025

The Impact of Artificial Lighting on the Visual Capacity of Patients With Age-Related Macular Degeneration

An observational study in AMD - Age-Related Macular Degeneration, sponsored by Democritus University of Thrace. Not yet recruiting at 1 site in Greece. Open to participants aged 60 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Democritus University of Thrace · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
70
Ages
60 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Macular Degeneration with a site in Greece — 5 open to participants now, 6 under way, 2 of them phase 3. Macular Degeneration · Greece.

Started
2025
with 4 others
Observational
8 of 18
1 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Democritus University of Thrace

Among the 18 studies in Macular Degeneration with a site in Greece, this one is one of 5 that started in 2025, is one of 8 observational ones, and was the 18th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

5 of the 18 studies in Macular Degeneration with a site in Greece are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 60 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Macular Degeneration with a site in Greece, or all of them as a file.
02

Study summary

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in the elderly worldwide. The dry, non-exudative form of the disease, although more common, is associated with gradual and significant decline in functional vision. Despite advancements in diagnostic and therapeutic approaches, a targeted intervention that improves the daily functionality of these patients is still lacking. One critical, yet often overlooked, factor that affects daily performance is lighting conditions.

This study aims to objectively assess the impact of different lighting intensity levels on patients with advanced dry AMD during the execution of everyday activities. A total of 60 individuals will be evaluated (30 healthy controls over 60 years of age and 30 patients with clinically diagnosed advanced AMD, according to NICE and AREDS criteria). Participants will undergo ophthalmological assessment (visual acuity, contrast sensitivity, OCT/OCTA, autofluorescence), and their performance on five functional tasks (mobility, object grasping, sit-to-stand transition, obstacle avoidance, and hanging clothes) will be evaluated under eight lighting levels (20-300 lux) at a constant color temperature (4000K), in a specially designed laboratory equipped with motion and eye-tracking systems.

The primary endpoint is overall performance, based on task completion time and errors, expressed on a custom performance scale (0-100). Secondary data include changes in pupil size as an indicator of visual adaptation. The study aims to determine the optimal lighting range that maximizes functional vision and improves the quality of life for patients with AMD.

Read the detailed description

Introduction Aging is associated with an increased prevalence of neurodegenerative disorders and leads to irreversible changes in both humans and animal models. The retina, a layer of neural tissue that lines the interior of the eyeball, is exposed to various harmful and stressful environmental factors, including age-related changes, which affect its function. Age-related macular degeneration (AMD) is the leading cause of visual decline and blindness worldwide in individuals aged 65 years and older. The number of patients suffering from AMD is expected to increase significantly in the coming decades. AMD primarily affects the macular region of the retina, which is responsible for central vision. It has a significant impact on patients' lives due to the loss of sharp and color vision, interfering with daily activities such as recognizing faces and reading.

To date, there is no proven treatment that slows or prevents the progression of advanced AMD. Laser photocoagulation and photodynamic therapy reduce the risk of moderate or severe vision loss in some individuals with the neovascular form of the disease. Other medical and surgical interventions are under investigation, but none have been shown to be effective. Identifying the exact pathophysiological mechanisms of AMD remains challenging. However, clinico-pathological observations and epidemiological studies have provided valuable insights into potential pathways involved in AMD development. AMD is generally classified into two forms: non-exudative (dry or atrophic) and exudative (wet).

Exudative AMD is characterized by the development of choroidal neovascularization (CNV), i.e., fibrovascular tissue that grows from the choriocapillaris, penetrates through breaks in Bruch's membrane into the sub-retinal pigment epithelium (RPE) space, and then under the neurosensory retina. Dry AMD involves dysfunction in the RPE-Bruch's membrane-choriocapillaris complex, resulting in lesions such as drusen (small, yellow-white deposits located mainly in the macular area), focal pigment clumping, and RPE atrophy. The most severe atrophic lesion observed in AMD is geographic atrophy, characterized by a well-demarcated round or oval area of depigmentation or clear absence of RPE cells.

The wet form of AMD represents less than 10% of cases but can lead to severe complications if untreated. The latest approach in CNV treatment includes intravitreal injections of anti-angiogenic agents. Vascular Endothelial Growth Factor (VEGF) plays a key role in angiogenesis and in the development of all forms of wet AMD, regardless of angiographic appearance, and increases vascular permeability. Anti-VEGF drugs aim to inhibit VEGF activity, thereby suppressing neovascular growth and reducing vascular leakage. However, this therapy merely delays disease progression. Thus, there is a need for novel preventive and therapeutic strategies targeting AMD.

One factor influencing AMD patients' ability to perform daily activities is lighting conditions. According to current literature, the ideal lighting conditions for AMD patients have not yet been thoroughly studied. Recently, our research team published a pioneering mathematical model to determine optimal lighting intensity in phakic and pseudophakic patients. Identifying optimal lighting for AMD patients could greatly enhance their quality of life.

It is also known that some individuals overestimate or underestimate their functional daily abilities based on self-assessed visual performance using questionnaires. Moreover, visual acuity alone is insufficient to provide a comprehensive assessment of patients' visual capacity. Ideally, any functional impairment should be objectively and realistically evaluated for each patient, either at home or in their work environment, by carefully assessing their performance in specific daily tasks.

Various activities have been developed to assess distance, as well as near and intermediate visual abilities. Mobility has been assessed in individuals with glaucoma using a specific framework of daily activities, and near/intermediate vision tasks have been evaluated in AMD patients. In contrast, performance in individuals with presbyopia and in those who have undergone presbyopia-correcting surgery has been evaluated using a different activity framework under stable or variable lighting conditions to determine optimal illumination levels.

Purpose The aim of this study is to evaluate the performance of patients with advanced-stage dry AMD in daily activities under different lighting conditions.

Method

This is a prospective observational comparative study involving a total of 60 participants, divided into two groups:

Healthy controls over the age of 60

Patients with bilateral diagnosed advanced AMD (according to the UK's National Institute for Health and Care Excellence-NICE-or AREDS 9-step classification), fulfilling at least one of the following criteria:

i) Geographic atrophy of the macula ii) Best-corrected visual acuity in the affected eye \<6/18 or logMAR >0.4 with dense/confluent drusen, advanced RPE changes, or vitelliform lesions iii) Fibrous scar iv) RPE tear v) Atrophy (absence/thinning of RPE and/or retina) vi) Cystoid degeneration (persistent intraretinal fluid or tubular structures unresponsive to therapy)

All participants will undergo a clinical evaluation at the Ophthalmology Outpatient Clinic and the Gait Analysis Laboratory of the University General Hospital of Evros. Initial assessments will include best-corrected monocular visual acuity using the validated DDiVAT chart and contrast sensitivity using the Pelli-Robson chart. Diagnostic evaluations will include macular optical coherence tomography (OCT), OCT angiography (OCT-A), and fundus autofluorescence imaging for AMD staging. All examinations will be conducted in accordance with standard clinical practice, without any interventional medical procedures.

Following clinical evaluation, participants will perform five daily activities under eight different lighting intensities (20, 50, 100, 125, 150, 200, 250, and 300 lux), with fixed light temperature (4000K). The performance will be assessed at the Gait Analysis Laboratory, which features a custom lighting setup of four adjustable light fixtures, installed based on a professional lighting design study.

The lab is equipped with an infrared motion-detection camera system, which, through special body-mounted reflectors, captures full-body movement, task duration, and motion fluidity in real time.

Additionally, the setup includes eye-tracking glasses, capable of measuring pupil size, blink rate, and saccadic eye movements. All devices are controlled by integrated software that extracts the data mentioned above. This system will be used to evaluate patients' performance in daily tasks under each lighting condition.

Daily Activities

Mobility: Patients walk a set distance along a corridor with grey obstacles at their self-selected pace.

Reach and grasp tasks: A white table is divided into 9 sections. Three small (24 mm), three medium (55 mm), and three large (73 mm) objects are randomly placed. Participants are asked to locate a specific object and place it on a marked black cross at a designated spot.

Sit-to-stand and stand-to-sit: Patients transition between two chairs placed opposite each other, repeating the sequence three times as fast as possible.

Overhead obstacle avoidance: Patients pass under a stretched rope placed at 1.5 m height.

Clothesline task: Patients pick up four differently colored garments from a basket and hang them on a fixed clothesline using clothespins.

Primary Outcome Activity Scores: Each participant's activity score will be calculated based on task completion time and errors. Errors will incur time penalties. A total completion time will be derived for each activity under each lighting condition. A custom scoring scale from 0 (lowest) to 100 (highest) will be developed. Each participant's performance score will be generated from this scale, determining the optimal lighting condition for AMD patients.

Secondary Outcome Pupil Size: The behavior of patients' pupil sizes under different lighting conditions will be assessed to correlate pupil response with light intensity.

Statistical Analysis An a priori power analysis was conducted. For an effect size of 0.17 of the activity score, 26 participants will be required in each study group to achieve a power of 0.8 at a significance level of 0.05. The normality of measurement data will be assessed using the Shapiro-Wilk test. Normally distributed data will be analyzed with the t-test. Non-normally distributed data will be analyzed with the Mann-Whitney U test. p-values \< 0.05 will be considered statistically significant. All statistical analyses will be performed using the Medcalc statistical software (Medcalc Software, Mariakerke, Belgium).

03

Conditions studied

  • AMD - Age-Related Macular Degeneration

Keywords

  • AMD
  • artificial lighting
  • ADLs
04

Who can participate

Ages eligible
60 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

  • Healthy controls over the age of 60
  • Patients with bilateral diagnosed advanced AMD (according to the UK's National Institute for Health and Care Excellence-NICE-or AREDS 9-step classification [13]), fulfilling at least one of the following criteria:

    i) Geographic atrophy of the macula ii) Best-corrected visual acuity in the affected eye \<6/18 or logMAR >0.4 with dense/confluent drusen, advanced RPE changes, or vitelliform lesions iii) Fibrous scar iv) RPE tear v) Atrophy (absence/thinning of RPE and/or retina) vi) Cystoid degeneration (persistent intraretinal fluid or tubular structures unresponsive to therapy)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy controls over the age of 60.
  • Diagnosis of bilateral dry age-related macular degeneration (AMD).

Exclusion criteria

Exclusion Criteria:

  • Patients with other ocular conditions such as high myopia, glaucoma, diabetic retinopathy, and other diseases that may confound the evaluation of ocular outcome measurements.
  • Patients who have undergone intraocular surgeries, except for uncomplicated cataract extraction surgery performed at least 3 months prior to their inclusion in the study.
  • Individuals with systemic diseases, including oxalate kidney stones, Wilson's disease, hemochromatosis, lung cancer, or other illnesses associated with poor five-year survival.
  • Patients with binocular best-corrected distance visual acuity less than or equal to hand motion perception.
  • Patients with neurological, orthopedic, or psychiatric disorders that prevent them from completing the activities or conditions that may affect their performance.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
70 participants (estimated)
Target follow-up
15 Days
Patient registry
Yes

Groups and cohorts

  • Control Group

    Healthy controls

    Diagnostic Test: Distant Visual Acuity · Diagnostic Test: Optical Coherence Tomography · Diagnostic Test: Optical Coherence Tomography Angiography

  • AMD Patients

    Patients with AMD stage 9 in both eyes.

    Diagnostic Test: Distant Visual Acuity · Diagnostic Test: Optical Coherence Tomography · Diagnostic Test: Optical Coherence Tomography Angiography · Diagnostic Test: Autofluorescence imaging

Interventions

  • Diagnostic testDistant Visual Acuity

    Distant Visual acuity of all participants using DDART web-application monocularly in both eyes.

  • Diagnostic testOptical Coherence Tomography

    Optical Coherence Tomography of the macula will be performed to all patients.

  • Diagnostic testOptical Coherence Tomography Angiography

    Optical Coherence Tomography Angiography of the macula will be performed to all patients.

  • Diagnostic testAutofluorescence imaging

    Autofluorescence imaging using fundus camera for AMD staging.

06

What researchers measure

Primary outcomes

  1. ADL score

    Each participant's activity score will be calculated based on task completion time and errors. Errors will incur time penalties. A total completion time will be derived for each activity under each lighting condition. A custom scoring scale from 0 (lowest) to 100 (highest) will be developed. Each participant's performance score will be generated from this scale, determining the optimal lighting condition for AMD patients.

    Time frame: On the same day as clinical evaluation, approximately 2-4 hours following baseline assessments.

Secondary outcomes

  1. Pupil Size

    The behavior of patients' pupil sizes under different lighting conditions will be assessed to correlate pupil response with light intensity.

    Time frame: On the same day as clinical evaluation, approximately 2-4 hours following baseline assessments.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Dec 2026, 18 months later.

Of 108 non-industry observational studies under Macular Degeneration, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 98. This study's planned 18 months is below that.

Counting every sponsor, half of 164 studies reached it within 44 months; a quarter within 15 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2025
First posted
Jul 11, 2025
StartEst.
Jun 30, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07060196
Lead sponsor
Democritus University of Thrace
Responsible party
Georgios Labiris (Associate Professor of Ophthalmology, Democritus University of Thrace) — Principal investigator
First posted
Jul 11, 2025
Start date
Jun 30, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jul 11, 2025

Study contacts

Minas Bakirtzis, MD, MSc
Contact
minas961@hotmail.com
+302551030990

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion